The UK Competition Authority fines several pharmaceutical companies for pay-for-delay settlements (GlaxoSmithKline)

CMA fines pharma companies £45 million* The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine. The CMA’s decision relates to conduct and agreements between 2001 and 2004 in which GlaxoSmithKline plc (GSK), the supplier of branded paroxetine (an anti-depressant medicine), agreed to make payments and other value transfers totalling over £50 million to suppliers of generic versions of paroxetine. The CMA has found that these payments and other value transfers were aimed at delaying the potential entry of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

UK Competition Authority, The UK Competition Authority fines several pharmaceutical companies for pay-for-delay settlements (GlaxoSmithKline), 12 February 2016, e-Competitions Bulletin February 2016, Art. N° 78295

Visites 101

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues